Thelansis

 Adult Neuronal Ceroid Lipofuscinosis (ANCL) constitutes a genetically diverse subgroup within the broader neuronal ceroid lipofuscinoses (NCLs) category. ANCL manifests in the third decade of life, marked by the onset of seizures, dementia, a decline in motor function, and, occasionally, visual impairment stemming from retinal degeneration. The ANCL phenotype was initially designated as CLN4 disease, but the responsible gene has yet to be identified. CLN4 can be inherited in either an autosomal recessive (referred to as CLN4A) or autosomal dominant (referred to as CLN4B) manner. The clinical presentation of ANCL typically involves the emergence of progressive myoclonic epilepsy or behavioral disturbances, followed by dementia and extrapyramidal motor symptoms, all typically appearing between the ages of 20 and 30. ·        The estimated prevalence of ANCL in the general population is approximately 1.5 individuals per 9,000,000.   Thelansis’...

  Adult neuronal ceroid lipofuscinosis (ANCL) is a genetically heterogeneous group of neuronal ceroid lipofuscinoses (NCLs) with onset during the 3rd decade of life, characterized by seizures, dementia and loss of motor capacities, and sometimes associated with visual loss due to retinal degeneration. It is also known as adult NCL, Kufs syndrome, Kufs disease, Parry disease, neuronal ceroid lipofuscinosis, and adult type. The ANCL prevalence is estimated to be about 1.5 people per 9,000,000 in the general population. Thelansis’s “Adult Neuronal Ceroid Lipofuscinosis (ANCL) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adult Neuronal Ceroid Lipofuscinosis (ANCL) treatment modalities o...